Mammography and Breast Arterial Calcification: An Information-Sharing Trial

Last updated: October 24, 2025
Sponsor: Icahn School of Medicine at Mount Sinai
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scleroderma

Hyperparathyroidism

Treatment

BAC-Enhanced Letter

Waitlist Control

Clinical Study ID

NCT04983875
Study-21-00112
R01CA251754
  • Ages > 40
  • Female

Study Summary

The purpose of this research study is to determine the potential benefits of adding information on patients' breast arterial calcification (BAC) results to the standard results letter women receive after mammography. In addition to looking for potential breast cancer, research shows that mammograms can also detect the presence of calcifications within the breast arteries. Those calcifications can be associated with coronary artery disease. Right now, women are not routinely told whether or not they have BAC; that is, it's not part of standard practice to communicate that information to patients. However, previous research has suggested that patients would like to be informed about their BAC status more often. In this study, the team has two goals. First, the team wants to measure the rates of BAC in a large, representative group of 3,700 women.

Second, the study team wants to understand the effects of giving women information on their BAC results as part of their standard post-mammography letter. Specifically, the study team wants to see how sharing that information might affect women's healthcare choices and lifestyle. The research will include 400 women in this second part of the study, which will be the first in the literature to explore women's reactions to BAC information. If research shows that women find the information useful, BAC information may be given to women regularly in the future.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Female

  • Scheduled to undergo mammography at one of Mount Sinai's breast radiology clinics (e.g., Dubin Breast Center, Radiology Associates)

  • Age ≥ 40 years

  • Read and speak English or Spanish

  • Ability to understand and the willingness to sign a written informed consent

  • Willing to sign and date any applicable medical record release documents for thestudy

Exclusion

Exclusion Criteria:

  • Participants with known coronary artery disease (via self-report)

  • Previous physician-diagnosed heart attack, stroke or TIA, heart failure, angina ortaking nitroglycerin, or atrial fibrillation (via self-report or review of EMR)

  • Inability to understand and comply with the instructions of the study due to thepresence of cognitive or psychiatric conditions (such as dementia, psychosis, ormania), compromising ability to provide informed consent and/or follow studyprocedures

  • Pregnant women

Study Design

Total Participants: 37000
Treatment Group(s): 2
Primary Treatment: BAC-Enhanced Letter
Phase:
Study Start date:
September 29, 2021
Estimated Completion Date:
March 31, 2027

Connect with a study center

  • Icahn School of Medicine at Mount Sinai

    New York, New York 10029
    United States

    Active - Recruiting

  • Mount Sinai

    New York, New York 10029
    United States

    Site Not Available

  • Mount Sinai

    New York 5128581, New York 5128638 10029
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.